[HIV-1 infection in blood donors and blood recipients]. 1990

Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
Zakład Serologii Instytutu Hematologii w Warszawie.

The results of the tests on HIV-1 infection in blood donors in the years 1985-1989 were presented. Out of 3.222.345 serum samples, in 66 donors HIV-1 antibodies were detected. In 1989 the significant raise of HIV-1 carriers, among whom there were 17 intravenous drug users, was noticed. The transmission of HIV-1 infection to 9 blood recipients was proved. Medical examination of 20 infected blood donors revealed in all of them the enlargement of peripheral lymph nodes. In 8 donors candidosis of oral cavity was diagnosed. The undertaken analysis showed the low efficacy of self deferral and pointed out that medical examination before blood donation should be more carefully done.

UI MeSH Term Description Entries
D008297 Male Males
D011044 Poland A country in central Europe, east of Germany. The capital is Warsaw. Polish People's Republic,Republic of Poland
D001782 Blood Donors Individuals supplying blood or blood components for transfer to histocompatible recipients. Blood Donor,Donor, Blood,Donors, Blood
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
September 1994, Lancet (London, England),
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
January 1988, Transfusion,
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
July 1988, New York state journal of medicine,
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
November 1992, European journal of epidemiology,
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
January 1991, Journal of acquired immune deficiency syndromes,
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
February 1990, Transfusion,
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
October 1991, JPMA. The Journal of the Pakistan Medical Association,
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
December 1987, AIDS (London, England),
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
July 1987, Lancet (London, England),
Z Moraczewska, and H Seyfriedowa, and E Kacperska, and W Szata, and W Mazurkiewicz, and L Babiuch
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Copied contents to your clipboard!